Abstract
The increasing trend of chiral drugs in the pharmaceutical industry has promoted greatly on the development of numerous biocatalytic routes in combination with chemical methods. Because the resulting chiral alcohols are particularly valuable intermediates and precursors for the synthesis of chiral drugs, dehydrogenases and reductases have been extensively used in the synthesis of chiral compounds from ketone substrates with high regio- and stereo-selectivities. In this review, biocatalytic processes carried out by dehydrogenases and reductases are described for the synthesis of chiral intermediates for a wide variety of pharmaceuticals, including antidepressants, anti-anxieties, anti-asthmatics, anti-hypertensives, cholesterol-lowering agents, NK1 antagonists, ACE inhibitors and β- Lactamase inhibitors.
Keywords: Biocatalysis, Dehydrogenases, Reductases, Chiral intermediates, Stereoselectivity, Cofactor regeneration
Current Organic Chemistry
Title: Dehydrogenases/Reductases for the Synthesis of Chiral Pharmaceutical Intermediates
Volume: 14 Issue: 14
Author(s): Yan Huang, Nan Liu, Xuri Wu and Yijun Chen
Affiliation:
Keywords: Biocatalysis, Dehydrogenases, Reductases, Chiral intermediates, Stereoselectivity, Cofactor regeneration
Abstract: The increasing trend of chiral drugs in the pharmaceutical industry has promoted greatly on the development of numerous biocatalytic routes in combination with chemical methods. Because the resulting chiral alcohols are particularly valuable intermediates and precursors for the synthesis of chiral drugs, dehydrogenases and reductases have been extensively used in the synthesis of chiral compounds from ketone substrates with high regio- and stereo-selectivities. In this review, biocatalytic processes carried out by dehydrogenases and reductases are described for the synthesis of chiral intermediates for a wide variety of pharmaceuticals, including antidepressants, anti-anxieties, anti-asthmatics, anti-hypertensives, cholesterol-lowering agents, NK1 antagonists, ACE inhibitors and β- Lactamase inhibitors.
Export Options
About this article
Cite this article as:
Huang Yan, Liu Nan, Wu Xuri and Chen Yijun, Dehydrogenases/Reductases for the Synthesis of Chiral Pharmaceutical Intermediates, Current Organic Chemistry 2010; 14 (14) . https://dx.doi.org/10.2174/138527210791616795
DOI https://dx.doi.org/10.2174/138527210791616795 |
Print ISSN 1385-2728 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5348 |
Call for Papers in Thematic Issues
Catalytic C-H bond activation as a tool for functionalization of heterocycles
The major topic is the functionalization of heterocycles through catalyzed C-H bond activation. The strategies based on C-H activation not only provide straightforward formation of C-C or C-X bonds but, more importantly, allow for the avoidance of pre-functionalization of one or two of the cross-coupling partners. The beneficial impact of ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Advanced Glycation End Products (AGEs) and Cardiovascular Disease (CVD) in Diabetes
Cardiovascular & Hematological Agents in Medicinal Chemistry Update on Cardiovascular Effects of Older and Newer Anti-diabetic Medications
Current Medicinal Chemistry Effects of Estrogens on Atherogenesis
Current Vascular Pharmacology Glucagon-Like Peptide 1 and the Cardiovascular System
Current Diabetes Reviews Contractile Mechanisms in Diabetes-Related Erectile Dysfunction
Current Pharmaceutical Design Screening of Antihypertensive Drugs for Osteoclastic Acid Secretion and Bone Resorption by Acridine Orange
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Resistin: An Inflammatory Cytokine. Role in Cardiovascular Diseases, Diabetes and the Metabolic Syndrome
Current Pharmaceutical Design Optimal antibiotic dosage for chronic kidney disease patient: a pharmacological manual for oral clinicians
Recent Patents on Anti-Infective Drug Discovery Stem Cells in Cardiovascular Regeneration: From Preservation of Endogenous Repair to Future Cardiovascular Therapies
Current Pharmaceutical Design Novel Inflammatory Biomarkers in Cardiovascular Therapeutics
Current Medicinal Chemistry Stage A: Can Heart Failure Be Prevented?
Current Cardiology Reviews Development and Evaluation of Transdermal Organogels Containing Nicorandil
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Nitric Oxide Synthase (NOS) as Therapeutic Target for Asthma and Chronic Obstructive Pulmonary Disease
Current Drug Targets Editorial (Thematic Issue: Antihypertensive Treatment in the Elderly)
Cardiovascular & Hematological Agents in Medicinal Chemistry Intracranial MR Dynamics in Clinically Diagnosed Alzheimers Disease: The Emerging Concept of “Pulse Wave Encephalopathy”
Current Alzheimer Research Platelets and Platelet Interaction with Progenitor Cells in Vascular Homeostasis and Inflammation
Current Vascular Pharmacology C-Reactive Protein and Hypertension: Is there A Causal Relationship?
Current Pharmaceutical Design Twin-to-Twin Transfusion Syndrome: From Placental Anastomoses to Long-Term Neurodevelopmental Outcome
Current Pediatric Reviews The Importance of Novel Inflammatory Biomarkers in Renal Disease
Current Medicinal Chemistry The Unaddressed Issue of Optimal Antithrombotic Treatment after Coronary Artery Stenting in Patients with an Indication for Anticoagulation: Current Evidence and Suggested Practice
Vascular Disease Prevention (Discontinued)